TScan Therapeutics (TCRX) Institutional Ownership → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free TCRX Stock Alerts $8.98 +0.08 (+0.90%) (As of 05/17/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for TScan Therapeutics (NASDAQ:TCRX)CurrentInstitutional OwnershipPercentage82.83%Number ofInstitutional Buyers(last 12 months)9TotalInstitutional Inflows(last 12 months)$11.82MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$68.21K Get TCRX Insider Trade Alerts Want to know when executives and insiders are buying or selling TScan Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data TCRX Institutional Buying and Selling by Quarter Ad Porter & CompanyObama’s Forever Term [exposed]America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.Start streaming it now at no cost here TScan Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/10/2024 Vanguard Group Inc.1,808,152$14.36M0.0%+1.1%3.776% 5/10/2024 Tocqueville Asset Management L.P.212,200$1.69M0.0%N/A0.443% 4/17/2024 Cannon Global Investment Management LLC17,500$139K0.4%N/A0.037% 2/14/2024 Pale Fire Capital SE21,573$126K0.0%+30.2%0.045% 2/12/2024 Letko Brosseau & Associates Inc.20,700$121K0.0%-36.1%0.043% 1/31/2024 abrdn plc200,000$1.17M0.0%N/A0.418% Get the Latest News and Ratings for TCRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for TScan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/14/2023 Pale Fire Capital SE16,575$42K0.0%N/A0.035% 11/9/2023 Letko Brosseau & Associates Inc.32,400$83K0.0%N/A0.068% 8/15/2023 BVF Inc. IL2,989,474$7.47M0.2%N/A12.338% 8/10/2023 Monashee Investment Management LLC400,000$1M0.2%N/A1.651% 7/26/2023 Privium Fund Management B.V.15,825$40K0.0%N/A0.065% 5/10/2023 Simplify Asset Management Inc.546,916$1.15M0.2%N/A2.257% 2/15/2023 Tang Capital Management LLC514,655$798K0.1%-7.8%2.137% 11/16/2022 Alphabet Inc.1,077,080$3.29M0.2%N/A4.482% 11/15/2022 Tang Capital Management LLC557,915$1.70M0.2%-25.4%2.322% 11/4/2022 Prudential Financial Inc.11,000$34K0.0%N/A0.046% 11/1/2022 Privium Fund Management UK Ltd15,825$48K0.1%N/A0.066% 5/17/2022 RA Capital Management L.P.1,021,764$2.86M0.1%-18.6%4.299% 5/17/2022 Hhlr Advisors LTD.669,513$1.88M0.0%-47.8%2.817% 4/26/2022 Marquette Asset Management LLC28,895$81K0.0%+33.7%0.122% 2/15/2022 Deer Management Co. LLC1,245,505$5.61M0.1%N/A5.240% 2/15/2022 Adage Capital Partners GP L.L.C.550,000$2.48M0.0%+10.8%2.314% 1/19/2022 Marquette Asset Management LLC21,618$97K0.0%N/A0.091% 11/16/2021 Schonfeld Strategic Advisors LLC22,200$185K0.0%N/A0.093% 11/16/2021 Wellington Management Group LLP139,566$1.16M0.0%N/A0.582% 11/15/2021 RA Capital Management L.P.1,255,317$10.47M0.1%N/A5.238% 11/15/2021 Caas Capital Management LP75,000$626K0.0%N/A0.313% 11/12/2021 DC Investments Management LLC35,563$297K0.6%N/A0.148% 11/12/2021 DC Funds LP630,000$5.25M20.6%N/A2.629% 11/9/2021 BlackRock Inc.1,500,577$12.52M0.0%N/A6.261% 11/9/2021 Monashee Investment Management LLC100,000$834K0.2%N/A0.417% (Data available from 1/1/2016 forward) TCRX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of TCRX shares? During the previous two years, 14 institutional investors and hedge funds held shares of TScan Therapeutics. The most heavily invested institutionals were Vanguard Group Inc. ($14.36M), BVF Inc. IL ($7.47M), Alphabet Inc. ($3.29M), Tocqueville Asset Management L.P. ($1.69M), abrdn plc ($1.17M), Simplify Asset Management Inc. ($1.15M), and Monashee Investment Management LLC ($1M).Learn more on TCRX's institutional investors. What percentage of TScan Therapeutics stock is owned by institutional investors? 82.83% of TScan Therapeutics stock is owned by institutional investors. Learn more on TCRX's institutional investor holdings. Which institutional investors have been buying TScan Therapeutics stock? Of the 13 institutional investors that purchased TScan Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: BVF Inc. IL ($2.99M), Alphabet Inc. ($1.08M), Simplify Asset Management Inc. ($546.92K), Monashee Investment Management LLC ($400K), Tocqueville Asset Management L.P. ($212.20K), abrdn plc ($200K), and Letko Brosseau & Associates Inc. ($32.40K). How much institutional buying is happening at TScan Therapeutics? Institutional investors have bought a total of 5,559,793 shares in the last 24 months. This purchase volume represents approximately $16.33M in transactions. Which TScan Therapeutics major shareholders have been selling company stock? The following institutional investors have sold TScan Therapeutics stock in the last 24 months: Tang Capital Management LLC ($233.15K), and Letko Brosseau & Associates Inc. ($11.70K). How much institutional selling is happening at TScan Therapeutics? Institutional investors have sold a total of 244,845 shares in the last 24 months. This volume of shares sold represents approximately $714.41K in transactions. Related Companies: Replimune Group Institutional Ownership Tourmaline Bio Institutional Ownership Ocugen Institutional Ownership Alvotech Institutional Ownership Solid Biosciences Institutional Ownership Fate Therapeutics Institutional Ownership Lexeo Therapeutics Institutional Ownership iTeos Therapeutics Institutional Ownership Black Diamond Therapeutics Institutional Ownership Adaptive Biotechnologies Institutional Ownership This page (NASDAQ:TCRX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBill Gates is all about this tiny $2 stockTimothy SykesThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsUrgent Nvidia WarningAltimetryCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.